Table 1 Clinical characteristics of patients in TCGA AML cohort
Characteristic | Low expression of FAAP24 | High expression of FAAP24 | P value |
|---|---|---|---|
n | 75 | 76 | Â |
Gender, n (%) | Â | Â | 0.028 |
 Female | 41 (27.2%) | 27 (17.9%) |  |
 Male | 34 (22.5%) | 49 (32.5%) |  |
Race, n (%) | Â | Â | 0.670 |
 Asian | 1 (0.7%) | 0 (0%) |  |
 Black or African American | 7 (4.7%) | 6 (4%) |  |
 White | 66 (44.3%) | 69 (46.3%) |  |
Age, n (%) | Â | Â | 0.357 |
 ≤ 60 | 47 (31.1%) | 41 (27.2%) |  |
 > 60 | 28 (18.5%) | 35 (23.2%) |  |
Cytogenetic risk, n (%) | Â | Â | 0.206 |
 Favorable | 20 (13.4%) | 11 (7.4%) |  |
 Intermediate | 38 (25.5%) | 44 (29.5%) |  |
 Poor | 17 (11.4%) | 19 (12.8%) |  |
FAB classifications, n (%) | Â | Â | 0.002 |
 M0 | 10 (6.7%) | 5 (3.3%) |  |
 M1 | 19 (12.7%) | 16 (10.7%) |  |
 M2 | 20 (13.3%) | 18 (12%) |  |
 M3 | 13 (8.7%) | 2 (1.3%) |  |
 M4 | 11 (7.3%) | 18 (12%) |  |
 M5 | 2 (1.3%) | 13 (8.7%) |  |
 M6 | 0 (0%) | 2 (1.3%) |  |
 M7 | 0 (0%) | 1 (0.7%) |  |
WBC (x10^9/L), median (IQR) | 14 (3, 42.25) | 28.5 (7, 54) | 0.062 |
BM blasts (%), median (IQR) | 37 (6, 67.5) | 40.5 (10.75, 63.25) | 0.537 |
PB blasts (%), median (IQR) | 69 (48, 86) | 72 (51, 84.25) | 0.542 |